News from Novartis Pharmaceuticals Corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 11, 2017, 11:03 ET Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study

Results from a post hoc subgroup analysis of the Phase II SUSTAIN study show that crizanlizumab, an investigational humanized anti-P-selectin...


Dec 07, 2017, 16:02 ET Novartis initiates study evaluating impact of higher dosing of Cosentyx® in patients with ankylosing spondylitis

Novartis announced today the initiation of the ASLeap trial in patients with ankylosing spondylitis (AS), evaluating the effect of changing to a...


Nov 14, 2017, 07:15 ET Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy

Novartis will present data across its breast cancer portfolio and pipeline in a broad range of patient populations, treatment combinations and...


Nov 01, 2017, 09:14 ET Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease

Novartis will present new data from across its hematology portfolio at the upcoming 59th American Society of Hematology (ASH) Annual...


Oct 24, 2017, 08:00 ET Novartis collaborates with pop icon Cyndi Lauper to release new song in honor of World Psoriasis Day

Novartis announced today that Grammy, Tony and Emmy award-winning singer, songwriter, actress and activist Cyndi Lauper has released a new song,...


Sep 14, 2017, 07:30 ET Novartis teams up with actress, producer and activist Eva Longoria to launch Kiss This 4 MBC™ to generate research funding and support for the metastatic breast cancer community

Novartis is teaming up with actress, producer and activist Eva Longoria to launch Kiss This 4 MBC™, a new initiative to increase much-needed...


Jul 14, 2017, 15:51 ET Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis

Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase...


May 26, 2017, 16:02 ET Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)

Novartis today announced the US Food and Drug Administration (FDA) approved the expanded use of Zykadia® (ceritinib) to include the first-line...


Mar 06, 2017, 01:30 ET Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause

Novartis announced today a new analysis (post hoc) of an uncontrolled extension study which shows moderate to severe plaque psoriasis patients...


Dec 09, 2016, 08:30 ET Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole

Novartis announced today additional analyses from the Phase III MONALEESA-2 study that show LEE011 (ribociclib) plus letrozole significantly...


Nov 16, 2016, 07:30 ET Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer

Novartis will present data demonstrating the latest advancements from its oncology research program at the 58th American Society of Hematology...


Nov 10, 2016, 08:00 ET Novartis partners with prominent US health advocacy organizations to launch first social networking platform for heart failure patients and their loved ones

Novartis Pharmaceuticals Corporation announced today the launch of Together in HF (www.TogetherinHF.com) – a social network for members of the...


Nov 01, 2016, 07:30 ET Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer

Novartis announced today that the US Food and Drug Administration (FDA) accepted the company's New Drug Application (NDA) for filing and granted...


Oct 08, 2016, 08:00 ET Novartis breakthrough therapy LEE011 (ribociclib) plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care

Results from the pivotal Phase III MONALEESA-2 study show LEE011 (ribociclib) plus letrozole significantly extended progression-free survival (PFS)...


Oct 01, 2016, 01:33 ET Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years

 Novartis announced today new data showing Cosentyx® (secukinumab) delivers efficacy in patients with moderate to severe plaque psoriasis...


Sep 23, 2016, 13:11 ET Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions

Novartis announced today that the US Food and Drug Administration (FDA) has granted three simultaneous approvals for the expanded use of...


Sep 19, 2016, 01:22 ET Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients

 A new post-hoc analysis demonstrates that the decline in health-related quality of life (HRQL) scores associated with a heart failure (HF)...


Sep 14, 2016, 07:30 ET Novartis survey published in The Breast Journal reveals major gaps in treatment discussions between metastatic breast cancer patients and doctors

Novartis announced today the publication of the Make Your Dialogue Count survey results in The Breast Journal, a first-of-its-kind survey designed...


Aug 03, 2016, 07:00 ET Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer

 Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib),...


Jul 07, 2016, 16:40 ET Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma

Novartis today announced that the US Food and Drug Administration (FDA) has approved an expanded age range for Xolair® (omalizumab) to include...


Jun 29, 2016, 17:15 ET Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)

 Novartis announced today that The New England Journal of Medicine (NEJM) published data for PKC412 (midostaurin) demonstrating an overall...


Jun 22, 2016, 11:35 ET Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology

 A new analysis published today in JAMA Cardiology has found that timely and broad adoption of Entresto® (sacubitril/valsartan) by all...


Jun 06, 2016, 14:40 ET Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma

 Novartis today announced data from a Phase III study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive...


Jun 04, 2016, 16:05 ET Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®

 Novartis today announced at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting, the first results from the Tasigna...